Spotlight On... Side-effects analysis gives Merck's new hep C med Zepatier an edge over older drugs; Lilly's Portrazza nabs NSCLC approval in Europe; Allergan's Avycaz gets FDA priority review for new use; and more...

Merck & Co.'s ($MRK) hep C combo Zepatier has just hit the market, but the drug is already winning kudos for its side-effects profile. In a new analysis of clinical trial data, Zepatier turned up proportionally fewer serious side effects than Gilead Sciences' ($GILD) hep C combo treatment Harvoni and its veteran hep C med Sovaldi. Overall, Advera Health Analytics' report deemed Zepatier safer than Sovaldi and on par with Harvoni. More from FiercePharmaMarketing

> European regulators blessed Eli Lilly's ($LLY) oncology med Portrazza as a treatment for patients with advanced non-small cell lung cancer. Report

> Allergan ($AGN) is a step closer to a new use for its infection-fighter Avycaz, as the FDA granted priority review to a new indication in complicated intra-abdominal infections. Release

> Astellas and Medivation ($MDVN) said the FDA is now reviewing an application to add new trial data to the labeling for their prostate cancer treatment Medivation. Release

> South Africa's Adcock Ingram says it's in advanced talks for a potential sale of its Indian sales and marketing unit. Report

And Finally... European drugmakers say a "Brexit" from the EU would threaten scientific research and jeopardize the current system of drug regulation in the region. Report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.